Evaluation of thrombophilic risk factors in patients diagnosed with pulmonary embolism: Single center experience

Objective: to evaluate the thrombophilic risk factors and incidence in patients presenting at the hematology outpatient clinic for further investigation after the diagnosis of pulmonary embolism. methodology: a total of 15 cases (8 male, 7 female) with the diagnosis of pulmonary embolism and referred to hematology clinic for investigating thrombophilic risk factors were retrospectively evaluated. thrombophilic screening tests for these patients are as follows: factor v leiden (fvl), prothrombin g20210 a (ptg) and methylentetrahydrofolate reductase (mthfr c677 t) gene mutations, protein c (pc), protein s (ps) and antithrombin iii (at iii) deficiency, active protein c resistance (apc-r), antinuclear antibodies (ana), anti dsdna, anticardiolipin antibodies igm and igg, lupus anticoagulant, homocysteine and factor viii levels were investigated. results: the commonest thrombophilic defect was mthfr c677t gene mutation (n=12) (80%). single defect (n=4) was found at a rate of 26.6%, double defects (n=2) 13.3%, triple defects (n=5) 33.3% and four defects (n=3) 20%. one patient had no defects. conclusion: in this retrospective study carried out in patients with pulmonary embolism, mthfr gene mutation was found to be the commonest cause for hereditary thrombophilia as a single risk factor and/or together with other thrombophilic risk factors.